SCHEMBL9909695

SCHEMBL9909695

Cc1nc2c(C(C)C)ccnc2[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.36
DAO P14920 3/20 0.36
GSK3A P49840 2/20 0.35
GSK3B P49841 2/20 0.35
CDK5 Q00535 2/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
ABL1 P00519 1/20 0.35
LCK P06239 1/20 0.35
FYN P06241 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
IGF1R P08069 1/20 0.35
FLT1 P17948 1/20 0.35
LTK P29376 1/20 0.35
KDR P35968 1/20 0.35
FLT3 P36888 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24423017 0.84 DAO (0.36) DAOGSK3AGSK3BCDK5AURKA
SCHEMBL12789750 0.83 DAO (0.39) DAOGSK3AGSK3BCDK5AURKA
SCHEMBL22304188 0.80 GSK3A (0.36) GSK3AGSK3BCDK5AURKADAPK3
SCHEMBL15925243 0.80 DAO (0.40) BRAFDAOAURKANSD2CASP6
SCHEMBL15925247 0.79 DAO (0.39) BRAFDAOAURKAAURKBNSD2
SCHEMBL24422535 0.77 GSK3B (0.36) GSK3AGSK3BCDK5AURKADAPK3
SCHEMBL24422924 0.76 ADORA3 (0.38) GSK3AGSK3BCDK5AURKAJAK2
SCHEMBL22304187 0.76 CDK5 (0.38) GSK3AGSK3BCDK5CDK7DYRK1A
SCHEMBL9909691 0.75 BRAF (0.35) BRAFDAOAURKA
SCHEMBL14764399 0.75 BRAF (0.45) BRAFGSK3AGSK3BCDK5HCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198279-B2 Pyrido[2,3-b]pyrazin-8-substituted compounds and their use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2012-06-12 US disclosed
US-20100298320-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298320-A1 Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use BRAF, NRAS, RAF1 BRAF 1/4885DAO 2675/4885GSK3A 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.